Related Experiment Video
Updated: May 8, 2026
10:01
Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
Published on: July 10, 2012
Clopidogrel reduces post-transplant obliterative bronchiolitis
Raimund H M Preidl1, Sebastian Eckl, Martina Ramsperger-Gleixner
1Department of Cardiac Surgery, Friedrich-Alexander University, Erlangen-Nürnberg, Germany.
Summary
Platelet inhibition with clopidogrel reduced airway obliteration in lung transplants. This treatment, alone or with other drugs, also decreased immune cell infiltration and inflammatory markers, improving transplant outcomes.
Area of Science:
- Transplantation immunology
- Immunopharmacology
- Graft rejection research
Background:
- Chronic lung allograft dysfunction (CLAD) limits survival after lung transplantation.
- Obliterative bronchiolitis is a key feature of CLAD, leading to graft failure.
- Investigating novel therapeutic targets for CLAD is crucial.
Purpose of the Study:
- To determine if clopidogrel-mediated platelet inhibition impacts obliterative bronchiolitis formation.
- To evaluate clopidogrel's efficacy alone and in combination with tacrolimus or everolimus.
- To analyze the effects of clopidogrel on immune cell infiltration and inflammatory markers.
Main Methods:
- Orthotopic tracheal transplantation in a mouse model (C57Bl/6 to CBA.J).
- Treatment with varying doses of clopidogrel, alone or combined with immunosuppressants.
- Histological and immunofluorescence analysis of grafts at multiple time points.
- Cytokine and alloantibody analysis using real-time PCR and FACS.
Main Results:
- Clopidogrel (20 mg/kg/day) significantly reduced tracheal graft obliteration compared to controls.
- Platelet inhibition led to decreased infiltration of T cells and macrophages.
- Treatment significantly lowered expression of key inflammatory cytokines and adhesion molecules.
- Combination therapy with everolimus or tacrolimus showed synergistic effects.
- Clopidogrel impaired donor-specific alloantibody production.
Conclusions:
- Platelet inhibition by clopidogrel effectively reduces fibrosis and obliteration in tracheal allografts.
- Clopidogrel offers a potential therapeutic strategy for mitigating CLAD development.
- Combination therapy may enhance the anti-obliterative effects of clopidogrel.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation